A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 260 (planned)
- Started
- Oct 18, 2022
- Main results expected
- Oct 12, 2026
- Fully finished
- Oct 12, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years
Number of participants with Serious AEs
Measured over: Up to approximately 4 years
Number of participants with AEs meeting protocol-defined DLT criteria
Measured over: Up to approximately 4 years
Number of participants with AEs leading to discontinuation
Measured over: Up to approximately 4 years
Number of deaths
Measured over: Up to approximately 4 years
Establish recommended Phase 2 dose (RP2D)
Measured over: Up to approximately 2 years
Establish dosing schedule of each combination for Part 2 Dose Expansion
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05372354 · record last updated 2025-09-05 · checked 2026-11-09 15:47 UTC